Overview


Glaucoma consists of a wide range of eye conditions that lead to damage in the optic nerve, a critical conduit for relaying visual information to the brain. While commonly associated with heightened eye pressure, glaucoma can also manifest even in cases of everyday stress. It is particularly prevalent in older people and constitutes a significant cause of blindness among individuals aged 60 and above.

The management of glaucoma encompasses a multifaceted approach aimed at alleviating intraocular pressure and safeguarding the integrity of the optic nerve. This involves a combination of medical, surgical, and lifestyle interventions tailored to each patient's needs. Medications, often in the form of prescribed eye drops, serve as a primary line of treatment, regulating the production and outflow of aqueous humor within the eye. Surgical options, ranging from laser trabeculoplasty to more invasive procedures like trabeculectomy or minimally invasive glaucoma surgery (MIGS), provide additional avenues for pressure reduction. Lifestyle adjustments, including regular exercise, a balanced diet rich in eye-friendly nutrients, and avoiding smoking, contribute to overall eye health. Consistent follow-up appointments with an ophthalmologist are paramount, ensuring timely adjustments to the treatment plan. Patient education and support are pivotal in empowering individuals with the knowledge to participate in their care actively. Stress management techniques and, in cases of familial predisposition, genetic testing, and family screening can further enhance the effectiveness of glaucoma management.

FutureWise Market Research has published a report that provides an insightful analysis of Anti-glaucoma Management Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Anti-glaucoma Management Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Aerie Pharmaceuyticals Inc
  • Allergan Plc
  • Bausch and Lomb Incorporated
  • Inotek Pharmaceuticals Corp
  • MerckCo. Inc
  • Novartis AG
  • Pfizer inc
  • Santen Pharmaceutical Co Ltd
  • SIFI S.p.S.
  • Teva Pharmaceutical Industries Ltd

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in the Anti Glaucoma Management Market

  • In April 2023, Celanese Corporation, a global company specializing in advanced materials and chemicals, announced a partnership with Glaukos Corporation. Celanese will provide its VitalDose Drug Delivery Platform to be incorporated into Glaukos’ iDose TR. This micro-invasive intraocular implant is designed to reduce intraocular pressure for individuals suffering from open-angle glaucoma or ocular hypertension as their primary condition.

Continued advancements in diagnostic tools, surgical techniques, and pharmaceuticals have improved the effectiveness and accessibility of glaucoma treatment, which is a significant factor in driving the market. With the increase in the aging population globally, there is a rise in glaucoma cases in the geriatric population, driving the market. Public and private organizations are organizing campaigns to educate people and regular eye checkups to increase awareness about glaucoma, propelling the market growth. The expansion of telemedicine and remote monitoring technologies allows for more accessible and convenient care for glaucoma patients and provides new opportunities for the market.in addition, the government is raising funds for more thorough research and development to integrate more innovative and affordable treatment options and bolster the market.

However, the high cost of the treatment, especially surgical procedures and therapeutics, can be expensive, which limits the accessibility and affordability for the patient population with inadequate funds and facilities. Limited skilled and trained professionals are available in remote areas, restraining market growth.

By Drug Class

  • Prostaglandin Analogs
  • Beta-Blockers
  • Alpha Adrenergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Combination Drugs
  • Others

By Indication

  • Open-angle Glaucoma
  • Angle Closure Glaucoma
  • Others

By End-user

  • Hospitals and Clinics
  • Surgical centers
  • Diagnostic Centers
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to the significant rise in the number of dry eye patients, increased prevalence of eye diseases, and awareness regarding the factors responsible for eye disease and precautions to be taken to prevent them. In addition, the government is raising funds to increase research and development in this field so more innovative treatment interventions and therapies can be discovered, propelling the market in this region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Anti-glaucoma Management Market By Drug Class, By Indication, By End-user and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Anti-glaucoma Management Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Anti-glaucoma Management Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Anti-glaucoma Management Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Anti-glaucoma Management Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Prostaglandin Analogs
        2. Beta-Blockers
        3. Alpha Adrenergic Agonists
        4. Carbonic Anhydrase Inhibitors
        5. Combination Drugs
        6. Others

  • 8.   Anti-glaucoma Management Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Open-angle Glaucoma
        2. Angle Closure Glaucoma
        3. Others

  • 9.   Anti-glaucoma Management Market, By End-user Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals and Clinics
        2. Surgical centers
        3. Diagnostic Centers
        4. Others

  • 10.   North America Anti-glaucoma Management Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Anti-glaucoma Management Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Anti-glaucoma Management Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Anti-glaucoma Management Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Aerie Pharmaceuyticals Inc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Allergan Plc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bausch & Lomb Incorporated
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Inotek Pharmaceuticals Corp
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Merck & Co. Inc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Novartis AG
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Pfizer inc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Santen Pharmaceutical Co Ltd
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. SIFI S.p.S.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Teva Pharmaceutical Industries Ltd
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

Related Market

Antiglaucoma Drugs Market

Read More

Glaucoma Treatment Market

Read More
Partner

Our Clients